Thyroid Cancer Clinical Trial
Official title:
Comparison of Quality of Life Between Patients With Early Differentiated Thyroid Cancer Undergoing Minimally Invasive and Open Surgery: A Prospective Cohort Study
The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Early differentiated thyroid cancer has a good prognosis, and surgery is the main treatment. Traditional open surgery would leave a scar on the neck. However, emerging minimally invasive procedures can avoid the scar on the neck, resulting in better aesthetic effect, which would have an impact on the quality of life of patients to a certain degree. This study intend to follow up patients regularly with early differentiated thyroid cancer undergoing different surgery. The quality of life, voice, scar would be assessed by authoritative questionaires or scales. We hope to demonstrate that minimally invasive surgery is better than traditional open surgery in order to provide reliable evidence for clinical practice.
Status | Recruiting |
Enrollment | 230 |
Est. completion date | September 10, 2025 |
Est. primary completion date | September 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Age =18 years and < 70 years; - Biopsy or surgical pathology indicated differentiated thyroid carcinoma (papillary thyroid carcinoma, follicular carcinoma); - stage T1~T3a, N0~N1a, M0; - Ability to read and write Chinese; - Willingness to follow up. Exclusion Criteria: - Age < 18 years old or =70 years old; - Biopsy or surgical pathology indicated medullary carcinoma or anaplastic thyroid carcinoma; - Aggressive histology: tall cell, columnar cell, hobnail variant, etc. - Mixed with medullary carcinoma or anaplastic thyroid carcinoma; - High risk of recurrence (according to ATA guideline); - Lateral cervical lymph node metastasis or distant metastasis; - Suffer from other malignant tumors; - History of thyroid surgery or cervical lymph node dissection; - Cognition or behavior impairment. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen Memorial Hopsital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of quality of life (SF-36) | change of the scores of the SF-36(36-item Short-Form)questionaire | baseline, 1month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Primary | change of quality of life (Thyca-Qol) | change of the scores of the Thyca-Qol(Thyroid Cancer-specific Quality of Life) questionaire | baseline, 1month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Secondary | voice handicap index | assessment of quality of voice | baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Secondary | scores of the surgical scar | scores of the questionaires (POSAS) about scar | 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Secondary | level of thyroglobulin | an indicator to monitor tumor residual or recurrence | baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Secondary | level of calcium | to indicate whether the patient have hypocalcemia | baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Secondary | operation duration | time for operation | Intraoperative | |
Secondary | blood loss | blood loss during operation | up to 1 week after surgery | |
Secondary | postoperative drainage | drainage volume after surgery | up to 1 week after surgery | |
Secondary | complications | complication events after surgery, e.g. hoarseness, hypocalcemia, hemorrhage, seroma | baseline, 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery | |
Secondary | satisfaction of the surgery | Visual Analog Score for satisfaction | 1 month after surgery, 3 months after surgery, 6 months after surgery, 12 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 | |
Completed |
NCT01964508 -
microRNA in Thyroid Cancer
|